Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells

Cell Death and Differentiation

Volumn 6, Issue 8, 1999, Pages 736-744

  Grusch, Michael ^a   Rosenberger, Georg ^a   Fuhrmann, Gerhard ^a   Braun, Katja ^a   Titscher, Birgit ^a   Szekeres, Thomas ^a   Fritzer Skekeres, Monika ^a   Oberhuber, Georg ^a   Krohn, Karsten ^b   Hengstschlaeger, Markus ^a   Krupitza, Georg ^a   Jayaram, Hiremagalur N ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF PADERBORN   (Germany)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Benzamide riboside; c myc induction; Cdc25A repression; Cyclin D1 prad 1 expression; IMP dehydrogenase inhibitor

Indexed keywords

BENZAMIDE; CELL CYCLE PROTEIN; DNA FRAGMENT; INOSINATE DEHYDROGENASE; MESSENGER RNA;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL STRUCTURE; HUMAN; HUMAN CELL; ONCOGENE C MYC; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032836084     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400546     Document Type: Article

References (50)

1. Jackson RC, Weber G and Morris HP (1975) IMP dehydrogenase: an enzyme linked with proliferation and malignancy. Nature 256: 331-333
2. Weber G (1983) Biochemical strategy of cancer cells and design of chemotherapy, G.H.A. Clowes Memorial Lecture. Cancer Res. 43: 3466-3492
3. Jayaram HN, Zhen W and Gharehbaghi K (1993) Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells. Cancer Res. 53: 2344-2348
4. Knight RD, Magnum J, Lucas DI, Cooney DA, Khan EC and Wright DG (1987) Inosine monophosphate dehydrogenase and myeloid cell development. Blood 69: 634-639
5. Jayaram HN, Dion RL, Glazer RI, Johns DG, Robins RK, Srivastava PC and Cooney DA (1982) Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC 286193). Biochem. Pharmacol. 31: 2371-2380
6. Tricot GJ, Jayaram HN, Lapis E, Natsumeda Y, Nichols CR, Kneebone P, Heerema N, Weber G and Hoffman R (1989) Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity. Cancer Res. 49: 3696-3701
7. Jayaram HN, Lapis E, Tricot G, Kneebone P, Paulik E, Zhen W, Engeler GP, Hoffman R and Weber G (1992) Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion. Int. J. Cancer 51: 182-188
8. Wright DG, Boosalis MS, Waraska K, Oshry LJ, Weeintraub LR andVosburgh E (1996) Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis. Anticancer Res. 16: 3349-3354
9. Krohn K, Heins H and Wielckens K (1992) Synthesis and cytotoxic activity of C-glycosidic nicotinamide riboside analogues. J. Med. Chem. 35: 511-517
10. Jayaram HN, Gharehbaghi K, Jayaram NH, Rieser J, Krohn K and Paull KD (1992) Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells. Biochem. Biophys. Res. Commun. 186: 1600-1606
11. Gharehbaghi K, Sreenath A, Hao Z, Paull KD, Szekeres T, Cooney DA, Krohn K and Jayaram HN (1994) Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin. Biochem. Pharmacol. 48: 1413-1419
12. Gharehbaghi K, Paull KD, Kelley JA, Barchi JJ, Marquez VE, Cooney DA, Monks A, Scudiero D, Krohn K and Jayaram HN (1994) Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase. Int. J. Cancer 56: 892-899
13. Cooney DA, Jayaram HN, Gebeyehu G, Betts CR, Kelley JA, Marquez VE and Johns DG (1982) The conversion of 2-β-D-ribofuranosylthiazole-4-carboxamide to an analog of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem. Pharmacol. 31: 2133-2136
14. Grunt T, Dittrich E, Somay C, Wagner T and Dittrich C (1991) Separation of clonogenic and differentiated cell phenotypes of ovarian cancer cells HOC-7 by discontinuous density gradient centrifugation. Cancer Lett. 58: 7-16
15. Krupitza G, Hulla W, Harant H, Dittrich E, Kallay E, Huber H, Grunt T and Dittrich C (1995) Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation. Int. J. Cancer 61: 649-657
16. Krupitza G, Harant H, Dittrich E, Szekeres T, Huber H and Dittrich C (1995) Sodium butyrate inhibits c-myc splicing and interferes with signal transduction in ovarian carcinoma cells. Carcinogenesis 16: 1199-1205
17. Vitale M, Zamai L, Mazzotti G, Cataldi A and Falcieri E (1993) Differential kinetics of propidium iodide uptake in apoptotic and necrotic thymocytes. Histochemistry 100: 223-229
18. Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA and Nicotera P (1995) Glutamate-induced neuronal cell death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15: 961-973
19. Niocotera P and Leist M (1997) Energy supply and the shape of death in neurons and lymphoid cells. Cell Death Differ. 4: 435-442
20. Krupitza G, Grusch M, Braun K, Fuhrmann G, Steinbrugger R, Hulla W, Simonitsch I, Chott A and Hengstschläger M (1998) TNF-mediated cell death is independent of Cdc25A. Cell Death Differ. 5: 758-764
21. Simonitsch I and Krupitza G (1998) Autocrine self elimination of cultured ovarian cancer cells by TNFa. Br. J. Cancer 78: 862-870
22. Marcu KB, Bossone SA and Patel AJ (1992) Myc function and regulation. Ann. Rev. Biochem. 61: 809-8'60
23. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M and Beach D (1995) Cdc25 Phosphatases as potential human oncogenes. Science 269: 1575-1577
24. Galakationov K, Chen X and Beach D (1996) Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382: 511-517
25. Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H and Okayarna H (1994) Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 13: 1549-1556
26. MacLachlan TK, Sang N and Giordano A (1995) Cyclins, cyclin dependent kinases and cdk inhibitors: implications in the cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Express 5: 127-156
27. Askew DS, Ashmun RC, Simmons BC and Cleveland JL (1991) Constitutive c-myc expression in an IL-3 dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6: 1915-1922
28. Evan G, Wyllie A, Gilbert C, Littlewood T, Land H, Brooks M, Waters C and Hancock D (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128
29. Klefstrom J, Vastrik I, Saksela E, Valle J, Eilers M and Alitalo K (1994) C Myc induces cellular susceptibility to the cytotoxic action of TNF-alpha. EMBO J. 13: 5442-5450
30. Vlach J, Hennecke S, Alevizopoulos K, Conti D and Amati B (1936) Growth arrest by the cyclin dependent kinase inhibitor p27 kip1 is abrogated by c-myc. EMBO J. 15: 6595-6604
31. Perez-Roger I, Solomon D, Sewing A and Land H (1997) Myc activation of cyclin E/Cdk-2 kinase involves induction of cyclin E gene transcription and inhibition of p27 Kip1 binding to newly formed complexes. Oncogene 14: 2373-2381
32. Pusch O, Bernaschek G, Eilers M and Hengstschläger M (1997) Activation of c-Myc uncouples DNA-replication from activation of G1-cyclin dependent kinases. Oncogene 15: 649-656
33. Galaktionov K, Jessus C and Beach D (1995) Raf interaction with Cdc25A phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev. 9: 1046-1058
34. Conklin D, Galaktionov K and Beach D (1995) 14-3-3 Proteins associate with Cdc25 phosphatases. Proc. Natl. Acad. Sci. USA 92: 7892-7896
35. Cleveland J, Troppmair J, Packham G, Askew D, Lloyd P, Gonzales-Garcia M, Nunez G, Ihle J and Rapp U (1994) v-Raf suppresses apoptosis and promotes growth of IL-3 dependent myeloid cells. Oncogene 9: 2217-2226
36. Kinoshita T, Shirouzu M, Kamyia A, Hashimoto K, Yokoyama S and Myijima A (1997) Paf/MAPK and rapamycin-sensitive pathways mediated the anti-apoptotic function of p21Ras in IL-3 dependent hematopoietic cells. Oncogene 7: 619-627
37. Canman C, Gilmer T, Coutts S and Kastan M (1995) Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 9: 600-611
38. Kasid U, Suy S, Dent P, Ray S, Whiteside T and Sturgill T (1996) Activation of raf by ionizing radiation. Nature 382: 813-816
39. Williams N and Roberts T (1994) Signal transduction pathways involving the raf proto-oncogene. Cancer Metastasis Rev. 13:105-116
40. Weissinger E, Eissner G, Grammar C, Fackler S, Haefner B, Yoon L, Lu K, Bazarov A, Sedivy J, Mischak H and Kolch W (1997) Inhibition of the Raf1 kinase by cAMP agonists causes apoptosis of v-abl transformed cells. Mol. Cell. Biol. 17: 3229-3241
41. Steiner P, Phillip A, Godden-Kent D, Pagano M, Mittnacht S, Bartek J and Eilers M (1995) Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J. 14: 4814-4826
42. Lenahan M and Ozer H (1996) Induction of c-myc mediated apoptosis in SV40-transformed rat fibroblasts. Oncogene 12: 1847-1854
43. Amati B, Alevizopoulos K and Vlach J (1975) Myc and the cell cycle. Frontiers Biosci. 3: 250-268
44. Spitovsky D, Jansen-Durr P, Karsenti E and Hoffman I (1996) S-phase induction by adenovirus E1A requires activation of cdc25A tyrosine phosphatase. Oncogene 12: 2549-2554
45. 0-like arrest. Mol. Cell. Biol. 16: 3934-3944
46. Schneider C, King L and Philipson L (1988) Genes specifically expressed at growth arrest of mammalian cells. Cell 54: 787-793
47. Motokura T and Arnold A (1993) Cyclins and oncogenesis. Biochem. Biophys. Acta 1155: 63-78
48. Draetta G (1994) Mammalian G1 cyclins. Curr. Opin. Cell Biol. 6: 842-846
49. Krupitza G, Fritsche R, Dittrich E, Harant H, Huber H, Grunt T and Dittrich C (1995) Macrophage colony-stimulating factor is expressed by an ovarian carcinoma subline and stimulates the c-myc proto-oncogene. Br. J. Cancer 72: 35-40
50. SoucekT, Pusch O, Hengstschläger-Ottnad E, Adams P and Hengstschläger M (1997) Deregulated expression of E2F-1 induces cyclin A- and E-associated kinase activities independently from cell cycle position. Oncogene 14: 2251-2257